Answers are grounded in this paper and cite their sources.
Objective: We compared economic outcomes when elderly patients with neuropsychiatric disorders received psychotropic medications guided by a combinatorial pharmacogenomic (PGx) test. Methods: This is a subanalysis of a 1-year prospective assessment of medication cost for patients with neuropsychiatric disorders receiving combinatorial PGx testing. Pharmacy claims were used to compare per member per year (PMPY) medication cost for patients ≥65 and <65 years old when medications were congruent or incongruent with the PGx test. Polypharmacy was also assessed. Results: Congruent prescribing was associated with savings of US$3497 PMPY ( P < .001) for patients ≥65 years and US$2467 PMPY ( P < .001) for patients <65, compared to incongruent prescribing. Congruent prescribing in patients ≥65 treated by primary care providers was associated with US$4113 PMPY ( P = .026) in savings, while congruent prescribing by psychiatrists was associated with US$120 PMPY ( P = .719). Congruent prescribing was also associated with one fewer neuropsychiatric medication for patients ≥65 ( P = .070). Conclusion: Congruence with PGx testing was associated with medication cost savings in elderly patients.
No takes yet. Share an insight, caveat, or question.
Jablonski et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: